De-escalation and escalation of treatment of patients with HER2-positive breast cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

On March 15, 2017, the 15th St. Gallen International Breast Cancer Conference (Vienna) examined controversial clinical issues with the goal of reaching agreement among the 50 most influential panel world leaders. Also, the results of randomized trials were examined in order to narrow or, conversely, expand the standards for local and systemic treatment. The introduction of trastuzumab in combination chemotherapy has significantly improved the results of treatment of HER2-positive breast cancer. Double inhibition of HER2 appears to be a promising strategy to improve the frequency of pCR and the survival rates in patients with breast cancer.

Full Text

Restricted Access

About the authors

V. F Semiglazov

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH

V. V Semiglazov

St. Petersburg State Medical University n.a. Acad. I.P. Pavlov of RMH

K. S Nikolaev

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH

Email: kirill.nikolaev87@gmail.com
Oncologist, Researcher at the Department of Breast Tumors

A. V Komyakhov

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH

T. Yu Semiglazova

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH

R. M Paltoev

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH

R. V Donskikh

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH

A. I Tseluyko

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH

A. S Artemyeva

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH

V. O Bashlyk

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH

G. F Miryusupova

Tashkent Pediatric Medical Institute

G. A Dashyan

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH

References

  1. Joensuu H. Escalating and de-escalating treatment in HER2-positive early breast cancer. Cancer Treat. Rev. 2017;52:1-11.
  2. Toi M., Lee S.J., Lee E.S., et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). San Antonio Breast Cancer Symposium 2015, 2015 Dec 8-12, San Antonio, TX (abstr S1-07).
  3. Gianni L., Pienkowski T., Im Y.H., Tseng L.M., Liu M.C., Lluch A., Starostawska E., de la Haba- Rodriguez J., Im S.A., Pedrini J.L., Poirier B., Morandi P, Semiglazov V., Srimuninnimit V., Bianchi G.V, Magazzû D., McNally V., Douthwaite H., Ross G., Valagussa P. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791-800.
  4. Hurvitz S.A., Martin M., Symmans W.F., et al. Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K])+pertuzumab (P) vs docetaxel+ carboplatin+trastuzumab+P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). J. Clin. Oncol. 2016;34(suppl):abstr 500.
  5. ParkJ.W., Liu M.C., Yee D., Yau C., van't Veer L.J., Symmans W.F., Paoloni M., Perlmutter J., Hylton N.M.,Hogarth M.,DeMichele A.,Buxton M.B., Chien A.J., Wallace A.M., Boughey J.C., Haddad T.C., Chui S.Y., Kemmer K.A., Kaplan H.G., Isaacs C., Nanda R., Tripathy D., Albain K.S., Edmiston K.K.,Elias A.D.,Northfelt D.W.,Pusztai L., Moulder S.L., Lang J.E., Viscusi R.K., Euhus D.M., Haley B.B., Khan Q.J., Wood W.C., Melisko M., Schwab R., Helsten T., Lyandres J., Davis S.E., Hirst G.L., Sanil A., Esserman L.J., Berry D.A.; 1-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer. N. Engl. J. Med. 2016;375(1):11-22
  6. Piccart-Gebhart M., Holmes E., Baselga J., de Azambuja E., Dueck A.C., Viale G., Zujewski J.A., Goldhirsch A., Armour A., Pritchard K.I., McCullough A.E., Dolci S., McFadden E., Holmes A.P, Tonghua L., Eidtmann H., Dinh P., Di Cosimo S., Harbeck N., Tjulandin S., Im Y.H., Huang C.S., Dieras V., Hillman D.W., Wolff A.C., Jackisch C., Lang I., Untch M., Smith I., Boyle F., Xu B, Gomez H., Suter T., Gelber R.D., Perez E.A. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J. Clin. Oncol. 2016;34(10):1034-42.
  7. Chan A., Delaloge S., Holmes F.A.,Moy B., Iwata H., Harvey V.J., Robert N.J., Silovski T., Gokmen E., von Minckwitz G., Ejlertsen B., Chia S.K., Mansi J., Barrios C.H., Gnant M., Buyse M., Gore I., Smith J. 2nd, Harker G., Masuda N., Petrakova K., Zotano A.G., Iannotti N., Rodriguez G., Tassone P., Wong A., Bryce R., Ye Y., Yao B., Martin M.; ExteNET Study Group. ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016; 17(3):367-77.
  8. van Ramshorst M.S.,vanderHeiden-vanderLoo M., Dackus G.M., Linn S.C., Sonke G.S. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res. Treat. 2016;158(2):361-71.
  9. Tolaney S.M., Barry W.T., Dang C.T., Yardley D.A., Moy B.,Marcom P.K.,Albain K.S.,Rugo H.S, Ellis M., Shapira I., Wolff A.C., Carey L.A., Overmoyer B.A., Partridge A.H., Guo H., Hudis C.A., Krop I.E., Burstein H.J., Winer E.P Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N. Engl. J. Med. 2015;372(2):134-41.
  10. Swain S.M, Kim S.B, Cortes J., Ro J.,Semiglazov V., Campone M., Ciruelos E., Ferrero J.M., Schneeweiss A., Knott A., Clark E., Ross G., Benyunes M.C., Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461-71.
  11. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., Pegram M., Oh D.Y., Dieras V., Guardino E., Fang L., Lu M.W., Olsen S., Blackwell K. EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2012;367:1783-91.
  12. Krop I.E., Kim S.B., Gonzalez-Martn A., LoRusso PM., Ferrero J.M., Smitt M., Yu R., Leung A.C., Wildiers H. TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689-99.
  13. Ellis P., Barrios C., Eiermann W., et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab± taxane (HT) rst-line treatment of HER2-positive MBC: primary results from the MARIANNE study. J. Clin. Oncol. 2015;33: abstr 507.
  14. Urruticoechea A., Rizwanullah M., Im S.A., et al. PHEREXA: A phase III study of trastuzumab (H)+capecitabine (X)±pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting. J. Clin. Oncol. 2016;34(suppl):abstr 504.
  15. Kaufman B.,Mackey J.R,Clemens M.R,Bapsy PP, Vaid A., Wardley A., Tjulandin S., Jahn M., Lehle M., Feyereislova A., Revil C., Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol. 2009;27:5529-37.
  16. Perez E.A., Barrios C., Eiermann W., Toi M., Im Y.H., Conte P., Martin M., Pienkowski T., Pivot X., Burris H. 3rd, Petersen J.A., Stanzel S., Strasak A., Patre M., Ellis P. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. J. Clin. Oncol. 2017;35(2):141-48.
  17. Arpino G., Ferrero J.M., de la Haba-Rodriguez J., et al. Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer. San Antonio Breast Cancer Symposium 2016, 2016 Dec 6-10, San Antonio, TX (abstr S3-04).
  18. von Minckwitz G., du Bois A., Schmidt M., Maass N., Cufer T., de Jongh F.E., Maartense E., Zielinski C., Kaufmann M., Bauer W., Baumann K.H., Clemens M.R., Duerr R., Uleer C., Andersson M., Stein R.C., Nekljudova V., Loibl S. Trastuzumab beyond pro-gression in human epidermal growth factor receptor 2-positive advanced reast cancer: a German Breast Group 26/breast international group 03-05 study. J. Clin.Oncol. 2009;27:1999-2006.
  19. Rayson D., Lutes S., Walsh G., Sellon M., Colwell B., Dorreen M., Drucker A., Jeyakumar A., Younis T. Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progressionfree survival on first-line therapy predicts overall survival impact. Breast J. 2014;20:408-13.
  20. Tripathy D., Rugo H.S., Kaufman P.A., Swain S., O'Shaughnessy J., Jahanzeb M., Mason G., Beattie M., Yoo B., Lai C., Masaquei A., Hurvitz S. The SystHERs registry: an observa-tional cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer. 2014;14:307.
  21. Andersson M., Lidbrink E., Bjerre K., Wist E., Enevoldsen K.,Jensen A.B., Karlsson P, Tange U.B., S0rensen R.G., M0ller S., Bergh J., Langkjer S.T. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J. Clin. Oncol. 2011;29: 264-71.
  22. Burstein H.J., Keshaviah A., Baron A.D., Hart R.D., Lambert-Falls R., Marcom P.K., Gelman R., Winer E.P Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007;110:965-72.
  23. Smyth L.M., Iyengar N.M., Chen M.F., Popper S.M., Patil S., Wasserheit-Lieblich C., Argolo D.F., Singh J.C., Chandarlapaty S., Sugarman S.M., Comen E.A., Drullinsky PR., Traina T.A., Troso-Sandoval T., Baselga J., Norton L., Hudis C.A., Dang C.T. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Res. Treat. 2016;158:91-7.
  24. Andersson M., Lopez-Vega J.M., Petit T., et al. The co-administration of pertu-zumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or meta-static breast cancer (MBC) patients (pts): VELVET study interim analysis. J. Clin. Oncol. 2015;33(15 suppl):586.
  25. Untch M., Jackisch C., Schneeweiss A., Conrad B., Aktas B., Denkert C., Eidtmann H., Wiebringhaus H.,Kümmei S.,Hiifrich J., WarmM.,Paepke S., Just M., Hanusch C., Hackmann J., Blohmer J.U., Clemens M., Darb-Esfahani S., Schmitt W.D., Dan Costa S., Gerber B., Engels K., Nekljudova V., Loibl S., von Minckwitz G.; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Investigators. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016;17:345-56.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies